0000000000142116

AUTHOR

Victor Mangas-sanjuan

showing 27 related works from this author

Erratum: Mangas-Sanjuán, V.; et al. Assessment of the Inter-Batch Variability of Microstructure Parameters in Topical Semisolids and Impact on the De…

2020

Demonstration of similar microstructure is essential for demonstrating the equivalence of generic topical products since the microstructure of semisolids may affect the drug release. The objective of this study was to compare the microstructure-defining physical parameters of different batches of a reference ointment containing calcipotriol and betamethasone (Daivobet 50 µg/0.5 mg/g) in order to define the acceptance range that allows concluding equivalence between these batches. Being batches of the same reference product, they are expected to be clinically equivalent and possess similar microstructure. The 90% confidence intervals for the test/reference ratio of these physical parameters …

lcsh:Pharmacy and materia medican/aPublished ErratumPharmaceutical ScienceThermodynamicsPharmaceuticslcsh:RS1-441ErratumMicrostructureEquivalence (measure theory)MathematicsPharmaceutics
researchProduct

The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives

2021

Immuno-oncology (IO) focuses on the ability of the immune system to detect and eliminate cancer cells. Since the approval of the first immune checkpoint inhibitor, immunotherapies have become a major player in oncology treatment and, in 2021, represented the highest number of approved drugs in the field. In spite of this, there is still a fraction of patients that do not respond to these therapies and develop resistance mechanisms. In this sense, mathematical models offer an opportunity to identify predictive biomarkers, optimal dosing schedules and rational combinations to maximize clinical response. This work aims to outline the main therapeutic targets in IO and to provide a description …

0301 basic medicineOncologymedicine.medical_specialtyComputer scienceImmune checkpoint inhibitorsPharmaceutical ScienceCancer immunityReview03 medical and health sciences0302 clinical medicinePharmacy and materia medicaDosing schedulesInternal medicinemedicineTumor growthimmuno-oncologyPK/PD modelsPredictive biomarkertop-down approachMathematical modelPK/PDmathematical modelingRS1-441030104 developmental biologybottom-up approach030220 oncology & carcinogenesisSpitemiddle-out approachPharmaceutics
researchProduct

A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.

2014

Oral administration of camptothecin (Cm) derivatives and other antitumoral agents is being actively developed in order to improve the quality of life of patients with cancer. Though several lipophilic derivatives of CPT have shown interesting oral bioavailability in preclinical and clinical studies, only Topotecan has been approved for this route of administration. Semisynthesis, antitumor activity, biological inhibition mechanism, and in situ intestinal permeability of 9, 10-[1,3]-Dioxinocamptothecin (CDiox), an unexplored CPT derivative, have been studied in this paper. The hexacyclic analog was as effective as Topotecan and CPT in different tumor cell lines, showing an expected similar a…

Oralendocrine system diseasesCellDioxinocamptothecinTransportAntineoplastic AgentsChemistry Techniques SyntheticPharmacologyPermeabilityHeLaQUIMICA ORGANICAPharmacokineticsOral administrationCell Line TumorDrug DiscoverymedicineAnimalsHumansheterocyclic compoundsIntestinal MucosaneoplasmsPharmacologybiologyChemistryOrganic ChemistryBiological TransportGeneral MedicineAntitumorbiology.organism_classificationSemisynthesisIn vitroRatsmedicine.anatomical_structureTopotecanCamptothecinCamptothecinmedicine.drugEuropean journal of medicinal chemistry
researchProduct

In vitro–in vivocorrelations: general concepts, methodologies and regulatory applications

2015

The major objective of in vitro-in vivo correlations is to be able to use in vitro data to predict in vivo performance serving as a surrogate for an in vivo bioavailability test and to support biowaivers. Therefore, the aims of this review are: (i) to clarify the factors involved during bio-predictive dissolution method development; and (ii) the elements that may affect the mathematical analysis in order to exploit all information available. This article covers the basic aspects of dissolution media and apparatus used in the development of in vivo predictive dissolution methods, including the latest proposals in this field as well as the summary of the mathematical methods for establishing …

PharmacologyChemistryChemistry PharmaceuticalOrganic ChemistryBiological AvailabilityPharmaceutical SciencePharmacologyIn vitroBioavailabilityIVIVCSolubilityIn vivoDrug DiscoveryAnimalsHumansIn vitro in vivoDrug Development and Industrial Pharmacy
researchProduct

Variability of permeability estimation from different protocols of subculture and transport experiments in cell monolayers.

2014

Abstract Introduction In vitro models with high predictive ability have been revealed as strong tools for pharmaceutical industry. However, the variability in permeability estimations complicates the comparison and combination of data from different laboratories and it makes necessary the careful validation of the model and the continuous suitability demonstration. The adequate standardization of pre-experimental, experimental and post-experimental factors might help to reduce the inter- and intra-laboratory variability in permeability values. Methods The objective of this paper is the evaluation of the effect of passage number, experimental protocol, time after seeding and calculation meth…

PharmacologyCell membrane permeabilityCell Membrane PermeabilityChemistryMadin Darby canine kidney cellCell Culture TechniquesNanotechnologyBiological Transportengineering.materialToxicologyMadin Darby Canine Kidney CellsRhodaminechemistry.chemical_compoundPermeability (earth sciences)DogsCoatingParacellular transportMonolayerengineeringBiophysicsAnimalsHumansCaco-2 CellsCells CulturedJournal of pharmacological and toxicological methods
researchProduct

Modified nonsink equation for permeability estimation in cell monolayers: comparison with standard methods.

2014

Cell culture permeability experiments are valuable tools in drug development and candidate selection, but the monolayer preparation protocols and the calculations procedures can affect the permeability estimation. Hence, standardization and method suitability demonstration are necessary steps for using permeability data for regulatory and in vivo prediction purposes. Much attention is usually paid to experimental procedure validation and less to the mathematical analysis of the results although the standard equations used imply several assumptions that many times do not hold. The aim of this study was to use a simulation strategy to explore the performance of a new proposed modified nonsink…

Apparent permeabilityAnalytical chemistryPharmaceutical ScienceRegression analysisPermeationStandard methodsModels TheoreticalPermeabilityPermeability (earth sciences)Drug DiscoveryLinear regressionModel simulationMolecular MedicineRegression AnalysisBiological systemMathematicsMolecular pharmaceutics
researchProduct

Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making

2021

Atorvastatin (ATS) is the gold-standard treatment worldwide for the management of hypercholesterolemia and prevention of cardiovascular diseases associated with dyslipidemia. Physiologically based pharmacokinetic (PBPK) models have been positioned as a valuable tool for the characterization of complex pharmacokinetic (PK) processes and its extrapolation in special sub-groups of the population, leading to regulatory recognition. Several PBPK models of ATS have been published in the recent years, addressing different aspects of the PK properties of ATS. Therefore, the aims of this review are (i) to summarize the physicochemical and pharmacokinetic characteristics involved in the time-course o…

Physiologically based pharmacokinetic modellingModel predictionAtorvastatinPopulationPharmaceutical ScienceReviewTarget populationComputational biologyP-glycoprotein030226 pharmacology & pharmacy03 medical and health sciencesPharmacy and materia medica0302 clinical medicinePharmacokineticsmedicineopen acid formeducationeducation.field_of_studybusiness.industrysolubilityatorvastatinactive metabolitesRS1-441lactonizationDose optimizationMetabolic enzymes030220 oncology & carcinogenesisbusinessmedicine.drugPharmaceutics
researchProduct

Estimators and confidence intervals of f2 using bootstrap methodology for the comparison of dissolution profiles

2021

Abstract Background and objectives: The most widely used method to compare dissolution profiles is the similarity factor f 2 . When this method is not applicable, the confidence interval of f 2 using bootstrap methodology has been recommended instead. As neither details of the estimator nor the types of confidence intervals are described in the guidelines, the suitability of five estimators and fourteen types of confidence intervals were investigated in this study by simulation. Methods: One million individual dissolution profiles were simulated for the reference and test populations with predefined target population f 2 values, where random samples of different sizes were drawn without rep…

PercentileSimilarity (network science)Sample size determinationStatisticsStatistical inferenceEstimatorHealth InformaticsPoint estimationExpected valueSoftwareConfidence intervalComputer Science ApplicationsMathematicsComputer Methods and Programs in Biomedicine
researchProduct

Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease

2020

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease characterized by an overexpression of epidermal growth factor receptor (EGFR). Nimotuzumab is a recombinant humanized monoclonal antibody against human EGFR. The aim of this study was to develop a population pharmacokinetic model for nimotuzumab and to identify demographic and clinical predictive factors of the pharmacokinetic variability. The population pharmacokinetics (PopPK) of nimotuzumab was characterized using a nonlinear mixed-effect modeling approach with NONMEM&reg

Oncologymedicine.medical_specialtyEGFRPopulationAutosomal dominant polycystic kidney diseasePharmaceutical SciencePhases of clinical researchlcsh:RS1-441030226 pharmacology & pharmacyArticlesemi-mechanistic pharmacokineticslcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicinepopulation analysismedicinePolycystic kidney diseaseNimotuzumabEpidermal growth factor receptoreducationNONMEMeducation.field_of_studybiologyautosomal dominant polycystic kidney diseasebusiness.industrynimotuzumabmedicine.diseaseNONMEM030220 oncology & carcinogenesisbiology.proteinbusinessmedicine.drugPharmaceutics
researchProduct

Innovative in Vitro Method To Predict Rate and Extent of Drug Delivery to the Brain across the Blood–Brain Barrier

2013

The relevant parameters for predicting rate and extent of access across the blood-brain barrier (BBB) are fu,plasma (unbound fraction in plasma), Vu,brain (distribution volume in brain) and Kp,uu,brain (ratio of free concentrations in plasma and brain). Their estimation still requires animal studies and in vitro low throughput experiments which make difficult the screening of new CNS candidates. The aim of the present work was to develop a new whole in vitro high throughput method to predict drug rate and extent of access across the BBB. The system permits estimation of fu,plasma, Vu,brain and Kp,uu,brain in a single experimental system, using in vitro cell monolayers in different condition…

MaleSwineChemistryHigh-throughput screeningDrug delivery to the brainAlbuminBrainPharmaceutical ScienceModels TheoreticalPharmacologyBlood–brain barrierIn vitroCell LineDogsDrug Delivery Systemsmedicine.anatomical_structureBlood-Brain BarrierIn vivoCell cultureDrug DiscoverymedicineAnimalsMolecular MedicineAnimal studiesMolecular Pharmaceutics
researchProduct

Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways …

2018

A semi-physiological two compartment pharmacokinetic model with two active metabolites (primary (PM) and secondary metabolites (SM)) with saturable and non-saturable pre-systemic efflux transporter, intestinal and hepatic metabolism has been developed. The aim of this work is to explore in several scenarios which analyte (parent drug or any of the metabolites) is the most sensitive to changes in drug product performance (i.e. differences in in vivo dissolution) and to make recommendations based on the simulations outcome. A total of 128 scenarios (2 Biopharmaceutics Classification System (BCS) drug types, 2 levels of KM Pgp, in 4 metabolic scenarios at 2 dose levels in 4 quality levels of t…

AnalyteCmaxPharmaceutical ScienceAdministration Oral02 engineering and technologyEquivalence Trials as TopicPharmacologyBioequivalence030226 pharmacology & pharmacyModels Biological03 medical and health sciencesFirst pass effect0302 clinical medicinePharmacokineticsHumansComputer SimulationPharmacokineticsIntestinal MucosaBiotransformationChemistryMembrane Transport Proteins021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemNONMEMNonlinear DynamicsPharmaceutical PreparationsSolubilityTherapeutic EquivalencyResearch DesignArea Under CurveLinear Models0210 nano-technologyMonte Carlo MethodDrug metabolismEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration

2019

Intravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodies has become the standard treatment for Age-Related Macular Degeneration; however, the knowledge of their pharmacokinetics is limited. A comprehensive review of the preclinical and clinical pharmacokinetic data that were obtained in different studies with intravitreal bevacizumab, ranibizumab, and aflibercept has been conducted. Moreover, the factors that can influence the vitreous pharmacokinetics of these drugs, as well as the methods that were used in the studies for analytical determination, have been exposed. These anti-VEGF drugs present different charge and molecular weights, which play an importan…

intravitrealgenetic structuresBevacizumabmedicine.medical_treatmentlcsh:RS1-441Pharmaceutical ScienceVitrectomyReviewvascular endothelial growth factor/antagonists &ampbevacizumabPharmacologylcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicinePharmacokineticsRanibizumabinhibitorsVascular endothelial growth factor/antagonists & inhibitorsMedicineDistribution (pharmacology)Pharmacokineticsranibizumab030304 developmental biologyAflibercept0303 health sciencesbusiness.industryafliberceptvascular endothelial growth factor/antagonists & inhibitorsIntravitreal administrationMacular degenerationmedicine.diseaseBevacizumabAge-Related Macular Degeneration030221 ophthalmology & optometryRanibizumabbusinessAfliberceptIntravitrealpharmacokineticsmedicine.drug
researchProduct

Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid

2015

Abstract The objective of this paper is to apply a previously developed semi-physiologic pharmacokinetic model implemented in NONMEM to simulate bioequivalence trials (BE) of acetyl salicylic acid (ASA) in order to validate the model performance against ASA human experimental data. ASA is a drug with first-pass hepatic and intestinal metabolism following Michaelis–Menten kinetics that leads to the formation of two main metabolites in two generations (first and second generation metabolites). The first aim was to adapt the semi-physiological model for ASA in NOMMEN using ASA pharmacokinetic parameters from literature, showing its sequential metabolism. The second aim was to validate this mod…

AnalyteChemistry PharmaceuticalMetaboliteCmaxPharmaceutical ScienceBioequivalencePharmacologyModels BiologicalBiomarkers PharmacologicalFirst pass effectchemistry.chemical_compoundPharmacokineticsIn vivoHumansMedicineComputer SimulationTissue DistributionBiotransformationChromatographyAspirinDose-Response Relationship Drugbusiness.industryHippuratesAnti-Inflammatory Agents Non-SteroidalNONMEMDrug LiberationTherapeutic EquivalencychemistryPharmacology ClinicalSalicylic AcidbusinessAlgorithmsSoftwareEuropean Journal of Pharmaceutical Sciences
researchProduct

Assessment of the Inter-Batch Variability of Microstructure Parameters in Topical Semisolids and Impact on the Demonstration of Equivalence

2019

Demonstration of similar microstructure is essential for demonstrating the equivalence of generic topical products since the microstructure of semisolids may affect the drug release. The objective of this study was to compare the microstructure-defining physical parameters of different batches of a reference ointment containing calcipotriol and betamethasone (Daivobet 50 &micro

microstructureequivalencelcsh:RS1-441Pharmaceutical Sciencegeneric semisolid formulation02 engineering and technology030226 pharmacology & pharmacyDosage formArticlelcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicinetopical drugStatisticsinter-batch variabilityEquivalence (measure theory)Parametric statisticsMathematics021001 nanoscience & nanotechnologyMicrostructureConfidence intervalReference productSample size determinationDrug releaserheology0210 nano-technologyPharmaceutics
researchProduct

Influence of Inter- and Intra-Batch Variability on the Sample Size Required for Demonstration of Equivalent Microstructure of Semisolid Dosage Forms

2020

Inter- and intra-batch variability of the quality attributes contribute to the uncertainty for demonstrating equivalent microstructure of post-approval changes and generic/hybrids of semisolid topical products. Selecting a representative sample size to describe accurately the in vitro properties of semisolids and to reach enough statistical power to demonstrate similarity between two semisolid topical products is currently challenging. The objective of this work is to establish the number of batches and units per batch to be compared based on different inter-batch and intra-batch variability to demonstrate equivalence in the physical characteristics of the products that ensure a similar mic…

Manufacturing processlcsh:RS1-441Pharmaceutical ScienceMicrostructureEquivalenceArticleStatistical powerDosage formIntra-batch variabilitylcsh:Pharmacy and materia medicaSample size determinationInter-batch variabilityBiological systemTopical productsMathematicsPharmaceutics
researchProduct

Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation.

2018

Regulatory guidelines recommend that, when a level A IVIVC is established, dissolution specification should be established using averaged data and the maximum difference between AUC and Cmax between the reference and test formulations cannot be greater than 20%. However, averaging data assumes a loss of information and may reflect a bias in the results. The objective of the current work is to present a new approach to establish dissolution specifications using a new methodology (individual approach) instead of average data (classical approach). Different scenarios were established based on the relationship between in vitro-in vivo dissolution rate coefficient using a level A IVIVC of a cont…

In vitro dissolutionCmaxPharmaceutical Science02 engineering and technologyBioequivalence021001 nanoscience & nanotechnology030226 pharmacology & pharmacyControlled releaseModels Biological03 medical and health sciencesDrug Liberation0302 clinical medicineIVIVCTherapeutic EquivalencyDelayed-Action PreparationsMaximum differenceRange (statistics)Computer Simulation0210 nano-technologyBiological systemDissolutionMonte Carlo MethodMathematicsTabletsEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder …

2020

Background: The aim of this analysis was to characterize the pharmacokinetics (PK) of sublingual buprenorphine (BUP) and its metabolites (buprenorphine glucuronide

PopulationCmaxbuprenorphine/naloxone sublingual filmlcsh:RS1-441Pharmaceutical SciencePharmacology030226 pharmacology & pharmacyArticlelcsh:Pharmacy and materia medica03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticspopulation pharmacokineticsNaloxonemedicine030212 general & internal medicineDosingNorbuprenorphinePuerto Ricanseducationeducation.field_of_studyopioid use disorder (OUD)business.industrypopPKchemistryGlucuronidebusinessSuboxonepharmacokineticsmedicine.drugBuprenorphinecompartmental modelingPharmaceutics
researchProduct

Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients.

2015

The objective of this paper was to validate a previously developed semi physiological model to simulate bioequivalence trials of drug products. The aim of the model was to ascertain whether the measurement of the metabolite concentration-time profiles would provide any additional information in bioequivalence studies (Fernandez-Teruel et al., 2009a,b; Navarro-Fontestad et al., 2010). The semi-physiological model implemented in NONMEM VI was used to simulate caffeine and its main metabolite plasma levels using caffeine parameters from bibliography. Data from 3 bioequivalence studies in healthy subjects at 3 different doses (100, 175 and 400mg of caffeine) and one study in cirrhotic patients …

Liver CirrhosisMetabolitePopulationPharmaceutical ScienceBioequivalencePharmacologyModels BiologicalIntestinal absorptionchemistry.chemical_compoundPharmacokineticsCaffeineMedicineHumansComputer SimulationeducationBiotransformationParaxanthineeducation.field_of_studyDose-Response Relationship Drugbusiness.industryReproducibility of ResultsHealthy VolunteersNONMEMchemistryIntestinal AbsorptionTherapeutic EquivalencyCentral Nervous System StimulantsCaffeinebusinessAlgorithmsEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

A multilevel object-oriented modelling methodology for physiologically-based pharmacokinetics (PBPK): Evaluation with a semi-mechanistic pharmacokine…

2019

Abstract Background and objective The aims of this study are (i) to assess the predictive reliability of the physiologically based software PhysPK versus the well-known population approach software NONMEM for the cited semi-mechanistic PK model, (ii) to determine whether these modelling approaches are interchangeable and (iii) to compare acausal with causal modelling approaches in the framework of semi-mechanistic PK models. Methods A semi-mechanistic model was proposed, which assumed oral administration of a solid dosage form with a peripheral compartment and two active metabolites. The model incorporates intestinal transit, dissolution limited by solubility, variable efflux transporter ex…

DrugPhysiologically based pharmacokinetic modellingComputer sciencemedia_common.quotation_subjectPopulationCmaxHealth InformaticsModels BiologicalDosage form030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineSoftwarePharmacokineticsPharmacokineticseducationmedia_commonVariable (mathematics)education.field_of_studybusiness.industryReproducibility of ResultsExpression (computer science)Computer Science ApplicationsNONMEMSolubilityArea Under CurvebusinessBiological system030217 neurology & neurosurgerySoftwareComputer methods and programs in biomedicine
researchProduct

Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.

2019

Aim The adequate dosing of topiramate in neonates undergoing therapeutic hypothermia has not been established. The aim of this study was to design a dosing schedule capable of providing topiramate serum concentrations within the accepted therapeutic range. Methods Neonates (n = 52) with hypoxic ischaemic encephalopathy and subjected to therapeutic hypothermia were dosed with topiramate, 5 mg/kg on day one and 3 mg/kg on days two to five, to decrease seizure events. A total of 451 topiramate serum concentrations obtained in the patients were used to develop a population pharmacokinetic model using a non-linear mixed-effects modelling approach. Results A one-compartment model with first-order…

TopiramatePopulationHypoxic ischaemic encephalopathyHypoxic Ischemic Encephalopathy03 medical and health sciences0302 clinical medicineTherapeutic indexPharmacokineticsHypothermia InducedSeizuresTopiramate030225 pediatricsMedicineHumans030212 general & internal medicineDosingeducationeducation.field_of_studybusiness.industryInfant NewbornGeneral MedicineHypothermiaAnesthesiaPediatrics Perinatology and Child HealthHypoxia-Ischemia Brainmedicine.symptombusinessmedicine.drugActa paediatrica (Oslo, Norway : 1992)REFERENCES
researchProduct

Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors.

2021

Simple Summary The clinical efficacy of immunotherapies when treating cold tumors is still low, and different treatment combinations are needed when dealing with this challenging scenario. In this work, a middle-out strategy was followed to develop a model describing the antitumor efficacy of different immune-modulator combinations, including an antigen, a toll-like receptor-3 agonist, and an immune checkpoint inhibitor in mice treated with non-inflamed tumor cells. Our results support that clinical response requires antigen-presenting cell activation and also relies on the amount of CD8 T cells and tumor resistance mechanisms present. This mathematical model is a very useful platform to ev…

AgonistCancer ResearchProgrammed cell deathmedicine.drug_classmedicine.medical_treatmentcold tumorscombination of therapeuticsArticleAntigenmedicinepreclinicalDoubling timeimmuno-oncologyRC254-282biologybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapydrug developmentmechanistic modelingOncologyDrug developmentCancer researchbiology.proteinAntibodybusinessCD8Cancers
researchProduct

Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing rec…

2020

Aims The aims are to develop a population pharmacokinetic model of capecitabine (CAP) and its main metabolites after the oral administration of CAP in colorectal cancer patients with different polymorphisms of the ATP-binding cassette (ABC) gene and a population pharmacokinetic/pharmacodynamic model capable of accounting for the neutropenic effects, and to optimize the dosing strategy based on the polymorphisms of the ABC gene and/or the administration regimen as a single agent or in combination. Methods Forty-eight patients diagnosed with colorectal cancer were included, with 432 plasma levels of CAP, 5'-desoxi-5-fluorouridine (5'-DFUR) and 5-fluorouracil (5-FU), and 370 neutrophil observa…

Colorectal cancerPopulationPharmacologyNeutropenia030226 pharmacology & pharmacyDeoxycytidinePolymorphism Single NucleotideCapecitabine03 medical and health sciences0302 clinical medicinePharmacokineticsOral administrationAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansPharmacology (medical)030212 general & internal medicineeducationCapecitabinePharmacologyeducation.field_of_studybusiness.industrymedicine.diseaseOxaliplatinPharmacodynamicsFluorouracilbusinessColorectal Neoplasmsmedicine.drugBritish journal of clinical pharmacologyREFERENCES
researchProduct

Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits.

2018

Abstract Marketed formulations of erythropoietin (EPO) ior®EPOCIM, MIRCERA® and two newly developed pegylated-EPO analogues (PEG-EPO 32 and 40 kDa) formulations were intravenously administered to New Zealand rabbits. A semi-mechanistic Pharmacokinetic/Pharmacodynamic (PK/PD) model describing in a simultaneous and integrated form the time course of reticulocytes, red blood cells and hemoglobin was built to account for the time course of hematopoiesis stimulation after erythropoietin administration. Data analysis was performed based on the population approach with the software NONMEM version 7.3. Erythropoietin disposition of each of the administered formulations was best described with a two…

MaleErythrocytesReticulocytesDrug CompoundingPopulationPharmaceutical ScienceBiological AvailabilityPharmacology030226 pharmacology & pharmacyModels BiologicalPolyethylene Glycols03 medical and health sciencesHemoglobins0302 clinical medicinePharmacokineticshemic and lymphatic diseasesMedicineAnimalseducationErythropoietinVolume of distributioneducation.field_of_studybusiness.industryRecombinant ProteinsNONMEMHematopoiesisHaematopoiesisErythropoietin030220 oncology & carcinogenesisPharmacodynamicsInjections IntravenousHematinicsLinear ModelsHemoglobinRabbitsbusinessmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Population pharmacokinetic model of lithium and drug compliance assessment.

2016

Population pharmacokinetic analysis of lithium during therapeutic drug monitoring and drug compliance assessment was performed in 54 patients and 246 plasma concentrations levels were included in this study. Patients received several treatment cycles (1-9) and one plasma concentration measurement for each patient was obtained always before starting next cycle (pre-dose) at steady state. Data were analysed using the population approach with NONMEM version 7.2. Lithium measurements were described using a two-compartment model (CL/F=0.41Lh-1, V1/F=15.3L, Q/F=0.61Lh-1, and V2/F = 15.8L) and the most significant covariate on lithium CL was found to be creatinine clearance (reference model). Lith…

OncologyAdultMalemedicine.medical_specialtyBipolar DisorderPopulationPopulationchemistry.chemical_elementRenal functionBiological AvailabilityLithium030226 pharmacology & pharmacy03 medical and health sciencesYoung Adult0302 clinical medicinePharmacokineticsAntimanic AgentsInternal medicineStatisticsCovariateMedicineHumansPharmacology (medical)educationBiological PsychiatryPharmacologyeducation.field_of_studyModels Statisticalmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryMiddle AgedMarkov ChainsNONMEMBioavailabilityPsychiatry and Mental healthNeurologychemistryTherapeutic drug monitoringLithium CompoundsPatient ComplianceLithiumFemaleNeurology (clinical)Drug Monitoringbusiness030217 neurology & neurosurgeryEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Mathematical modeling of oral absorption and bioavailability of a fluoroquinolone after its precipitation in the gastrointestinal tract

2013

The objective was to characterize the in vivo absorption and bioavailability (BA) of a low solubility, high permeability fluoroquinolone (CNV97101) that precipitates in the gastrointestinal (GI) tract by mathematical modeling approach. In situ rat intestinal perfusion studies were performed to characterize the absorption mechanism. The oral fraction absorbed in vivo was lower than the predicted based on the in situ intestinal permeability. Two additional routes of administration, intraduodenal (ID) and intraperitoneal (IP) were investigated to explore if precipitation in stomach and subsequent partial re-dissolution were the causes of the lower in vivo BA. Ex vivo precipitation studies with…

Health Toxicology and MutagenesisAdministration OralBiological AvailabilityPharmacologyToxicologyBiochemistryPermeabilityIntestinal absorptionPharmacokineticsCiprofloxacinIn vivomedicineAnimalsChemical PrecipitationChromatography High Pressure LiquidPharmacologyGastrointestinal tractIntestinal permeabilityChemistryStomachGeneral MedicineHydrogen-Ion ConcentrationModels Theoreticalmedicine.diseaseRatsBioavailabilityGastrointestinal Tractmedicine.anatomical_structureIntestinal AbsorptionNonlinear DynamicsSolubilityEx vivoFluoroquinolonesXenobiotica
researchProduct

Drug gastrointestinal absorption in rat: Strain and gender differences.

2015

Predictive animal models of intestinal drug absorption are essential tools in drug development to identify compounds with promising biopharmaceutical properties. In situ perfusion absorption studies are routinely used in the preclinical setting to screen drug candidates. The objective of this work is to explore the differences in magnitude and variability on intestinal absorption associated with rat strain and gender. Metoprolol and Verapamil absorption rate coefficients were determined using the in situ closed loop perfusion model in four strains of rats and in both genders. Strains used were Sprague-Dawley, Wistar-Han, Wistar-Unilever, Long-Evans and CD∗IGS. In the case of Metoprolol only…

DrugAbsorption (pharmacology)Malemedia_common.quotation_subjectPharmaceutical SciencePharmacologyIntestinal absorptionRats Sprague-DawleySpecies SpecificitymedicineAnimalsRats Long-EvansRats Wistarmedia_commonMetoprololSex CharacteristicsIntestinal permeabilityChemistrymedicine.diseaseIntestinal AbsorptionVerapamilPermeability (electromagnetism)VerapamilFemalePerfusionmedicine.drugMetoprololEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Comparison of free software platforms for the calculation of the 90% confidence interval of f2 similarity factor by bootstrap analysis

2020

Abstract Introduction The calculation of the 90% confidence interval of f2 based on the bootstrap methodology has been proposed and accepted by the main regulatory authorities when the dissolution data shows excessive variability. Different free software platforms allow the calculation of the 90% CI of f2 by means of bootstrapping. Their use in regulatory submissions is growing, but divergent results have been observed between the available software platforms. Therefore, the objective of this work is to analyze the characteristics of these software platforms and evaluate their results. Methods and materials Highly variable in vitro dissolution data from two products were selected. Three dif…

Percentilebusiness.industryPharmaceutical ScienceValue (computer science)02 engineering and technology021001 nanoscience & nanotechnology030226 pharmacology & pharmacyConfidence interval03 medical and health sciencesVariable (computer science)0302 clinical medicineSoftwareBootstrapping (electronics)Similarity (network science)StatisticsTruncation (statistics)0210 nano-technologybusinessMathematicsEuropean Journal of Pharmaceutical Sciences
researchProduct